Summit Therapeutics SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Other events · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics Announces Planned Phase III HARMONi-10 Trial of Ivonescimab vs Durvalumab in Stage III NSCLC
Other events · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics Receives FDA Complete Response Letter for Ivonescimab BLA in Second-Line EGFR-Mutated NSCLC, Citing Lack of Statistically Significant Overall Survival Benefit
Results of operations and financial condition · Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics Q3 2026 non-GAAP net loss of $0.20 per share, in line with consensus; GAAP loss $0.26 per share, narrower than $0.31 a year earlier
Other events · Financial statements and exhibits
AI summary, unreviewedSummit Therapeutics files legal opinion (Exhibit 5.1) tied to prospectus supplement under its S-3 shelf registration
Entry into a material definitive agreement · Unregistered sales of equity securities · Amendments to articles or bylaws; fiscal year change · Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits
Other events · Financial statements and exhibits